Kinetic characteristics of biochemical parameters during consupren therapy after allogenic transplantation of the kidney

Changes in biochemical and common clinical parameters of the blood were detected in patients treated with consupren (cyclosporin) as the main immunosuppressant after allogenic transplantation of the kidney. Kinetic model for evaluation of treatment adequacy was based on therapeutic drug monitoring and monitoring of blood biochemistry in recipients of the primary kidney transplant. The k1, t1/2, C0, clearance (for hemoglobin), conditioned volume of distribution (for cyclosporin) of processes of biochemical parameters (toxicity markers) stabilization within the framework of a single-part kinetic model were determined. © Springer Science+Business Media, Inc. 2004

Natriuretic peptides and Galectin-3 in senile heart failure patients with preserved ejection fraction.

Purpose: to characterize biomarker panel in senile patients with heart failure with preserved ejection fraction (HF-pEF). Material and Methods. 356 senile patients with chronic heart failure with preserved ejection fraction (HFpEF) were examined to form the study sample of 48 male patients without atrium fibrillation, anemia, diabetes mellitus, onco-pathology and missing clinical data. NT-proBNP, galectin-3 (gal-3) and proANT assay was performed by commercially available ELISA kits. Results. In patients without left ventricular (LV) regional wall motion abnormalities (RWMA). gal-3 (2,13 (0,98; 3,50) vs 5.16 (4,34;9.63) ng/mL, p = 0.011) and NT-proBNP (5,59 (1,00; 10.13) vs 32,04 (15,40; 46,18) fmol/mL, p=0,006) levels were significantly lower than in patients with LV RWMA. Contrarily proANP level was lower in patients with LV RWMA (3,24 (2,47; 3,75) vs 1,38 (0,83; 2,29) nmol/mL, p=0.071). proANP was the only biomarker to increase significantly in long livers (7,30 (4,52; 7,63) vs 2,68 (1,88; 3,32) nmol/mL, p=0.006). NT-proBNP positively correlated with glucose level and negatively with hsCRP (R=0,52, p=0,007). Conclusion. Biomarker panel in senile heart failure patients with preserved ejection fraction has characterized: increase in NT-proBNP and galectin-3 is associated with more severe clinical course and presence of regional wall motion abnormalities in senile patients.</p

Kinetic characteristics of biochemical parameters during consupren therapy after allogenic transplantation of the kidney

Changes in biochemical and common clinical parameters of the blood were detected in patients treated with consupren (cyclosporin) as the main immunosuppressant after allogenic transplantation of the kidney. Kinetic model for evaluation of treatment adequacy was based on therapeutic drug monitoring and monitoring of blood biochemistry in recipients of the primary kidney transplant. The k1, t1/2, C0, clearance (for hemoglobin), conditioned volume of distribution (for cyclosporin) of processes of biochemical parameters (toxicity markers) stabilization within the framework of a single-part kinetic model were determined. © Springer Science+Business Media, Inc. 2004

РАЗРАБОТКА И ВАЛИДАЦИЯ МЕТОДИКИ КИНЕТИЧЕСКОЙ ОЦЕНКИ РАСТВОРЕНИЯ ЛЕКАРСТВЕННОЙ СУБСТАНЦИИ ТОПИРАМАТ МЕТОДОМ ЛАЗЕРНОЙ ДИФРАКЦИИ СВЕТА

Solubility is the most important quality indicator, reflecting the physicochemical properties of active pharmaceutical ingredients (APIs). Prior to the release of API, solubility is one of the key factors affecting the efficacy and safety of drugs. Therefore, the directed development of new drugs with predetermined properties (drug design) should be basedon solubility of candidate substances and be taken into account when evaluating the bioequivalence of generic drugs branded, including in vitro - in vivo correlation. Given that the pharmacopeia regulation of the test for the solubility of API is reduced to a visual estimate and approximate solubility, we developed a kinetic dissolution evaluation method by laser diffraction and performed statistical analysis of the results obtained under repeatability conditions.Растворимость - важнейший показатель качества, отражающий физико-химические свойства активных фармацевтических ингредиентов (АФИ). Предшествующая высвобождению АФИ, растворимость является одним из ключевых факторов, влияющих на эффективность и безопасность лекарственного средства. Поэтому направленная разработка новых лекарственных препаратов с заранее заданными свойствами (drug design) должна основываться в том числе на данных о растворимости веществ-кандидатов и учитываться при оценке биоэквивалентности дженериковых препаратов брендовым, в том числе при выявлении корреляции in vitro - in vivo. С учетом того, что фармакопейное регламентирование проведения теста на растворимость АФИ сводится к визуальной оценке и приблизительной растворимости, нами разработана методика кинетической оценки растворения методом лазерной дифракции и проведена статистическая обработка полученных результатов в условиях повторяемости

РАЗРАБОТКА И ВАЛИДАЦИЯ МЕТОДИКИ КИНЕТИЧЕСКОЙ ОЦЕНКИ РАСТВОРЕНИЯ ЛЕКАРСТВЕННОЙ СУБСТАНЦИИ ТОПИРАМАТ МЕТОДОМ ЛАЗЕРНОЙ ДИФРАКЦИИ СВЕТА

Solubility is the most important quality indicator, reflecting the physicochemical properties of active pharmaceutical ingredients (APIs). Prior to the release of API, solubility is one of the key factors affecting the efficacy and safety of drugs. Therefore, the directed development of new drugs with predetermined properties (drug design) should be basedon solubility of candidate substances and be taken into account when evaluating the bioequivalence of generic drugs branded, including in vitro - in vivo correlation. Given that the pharmacopeia regulation of the test for the solubility of API is reduced to a visual estimate and approximate solubility, we developed a kinetic dissolution evaluation method by laser diffraction and performed statistical analysis of the results obtained under repeatability conditions.Растворимость - важнейший показатель качества, отражающий физико-химические свойства активных фармацевтических ингредиентов (АФИ). Предшествующая высвобождению АФИ, растворимость является одним из ключевых факторов, влияющих на эффективность и безопасность лекарственного средства. Поэтому направленная разработка новых лекарственных препаратов с заранее заданными свойствами (drug design) должна основываться в том числе на данных о растворимости веществ-кандидатов и учитываться при оценке биоэквивалентности дженериковых препаратов брендовым, в том числе при выявлении корреляции in vitro - in vivo. С учетом того, что фармакопейное регламентирование проведения теста на растворимость АФИ сводится к визуальной оценке и приблизительной растворимости, нами разработана методика кинетической оценки растворения методом лазерной дифракции и проведена статистическая обработка полученных результатов в условиях повторяемости

Virus-like particles as a vaccine delivery system: myths and facts.

Vaccines against viral disease have traditionally relied on attenuated virus strains or inactivation of infectious virus. Subunit vaccines based on viral proteins expressed in heterologous systems have been effective for some pathogens, but have often suffered from poor immunogenicity due to incorrect protein folding or modification. In this chapter we focus on a specific class of viral subunit vaccine that mimics the overall structure of virus particles and thus preserves the native antigenic conformation of the immunogenic proteins. These virus-like particles (VLPs) have been produced for a wide range of taxonomically and structurally distinct viruses, and have unique advantages in terms of safety and immunogenicity over previous approaches. With new VLP vaccines for papillomavirus beginning to reach the market place we argue that this technology has now 'come-of-age' and must be considered a viable vaccine strategy